Loading
Juniper Biosciences develops radioactive scan agents and treatments for cancer. Its most advanced product is a PET tracer that shows low-oxygen areas in HPV-positive head and neck cancers, which could help doctors tailor radiotherapy.
Juniper Biosciences LLC is a New Jersey radiopharmaceutical company developing diagnostic and therapeutic agents for oncology. It announced an oversubscribed, upsized USD 40 million seed financing on 1 December 2025 through its parent Juniper Radiopharma LLC, co-led by NovaCapital, high-net-worth individuals and members of the Club degli Investitori; Alex Agnoletto is CEO. Its pipeline lists JBS-003 (F-MISO, fluorine-18 fluoromisonidazole) for imaging hypoxic tumour cells in HPV-positive head and neck cancer, which the company says has FDA Breakthrough Therapy Designation; JBS-002, a gallium-68 PSMA agent; JBS-004, a fluorine-18 tracer for Alzheimer's disease; and JBS-005, undisclosed alpha, beta and gamma emitter programmes.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Seed | 2025 | $40M | santelog.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Shares PET (positron emission tomography), PSMA, Prostate cancer.
Shares PET (positron emission tomography), PSMA, PSMA PET, Prostate cancer.
Shares PET (positron emission tomography), PSMA, PSMA PET, Prostate cancer.
Shares PET (positron emission tomography), PSMA, PSMA PET, Prostate cancer.
Shares HPV-positive oropharyngeal cancer, Head and neck squamous cell carcinoma.
Shares PSMA, PSMA PET, Prostate cancer.
Shares PSMA, PSMA PET, Prostate cancer.
Shares Tumour hypoxia: imaging and modification, Head and neck squamous cell carcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/